Home » Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study – PMC
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study – PMC
by Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T Bourlon, Helen Moon, Raffaele Ratta, Rana R McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel YC Heng, Edgar Braendle, Kathryn E Beckermann, Bradley A McGregor & Robert J Motzer | Oct 5, 2025 | Articles |
